



## News Release

### Suven's PAT up by 500 % for the Qtr ended Dec 2012

**HYDERABAD, INDIA (12 Feb' 2013)** – SUVEN LIFE Sciences Limited, a biopharmaceutical company specializing in drug discovery and developmental activities in Central Nervous System disorders, today announced its un-audited financial results for the quarter ended 31<sup>st</sup> Dec 2012. The un-audited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on 12<sup>th</sup> Feb, 2013 at Hyderabad.

#### Financial Highlights for the 3<sup>rd</sup> Quarter ended Dec' 2012:

Growth in revenue	Rs 628 mil vs. Rs 502 mil	- Up by 25 %
Growth in PAT	Rs 78 mil vs. Rs 13 mil	- Up by 500 %
Growth in EBIDTA	Rs 152 mil vs. Rs 21 mil	- Up by 613 %

#### Financial Highlights for the 9 months ended Dec' 2012:

Growth in revenue	Rs 1837 mil vs. Rs 1447 mil	- Up by 27 %
Growth in PAT	Rs 222 mil vs. Rs 72 mil	- Up by 208 %
Growth in EBIDTA	Rs 401 mil vs. Rs 115mil	- Up by 248 %

Suven's major thrust on innovative R&D in Drug Discovery continues with a spending of Rs 249 mil (13.54 % on revenue) for the period 9 months ended Dec ' 2012.

During the quarter there were major qualitative achievements with the grant of 8 (eight) product patents from Canada, China, Eurasia and Korea to Suven's drug discovery pipeline which consists of 13 molecules out of which twelve (12) molecules currently in pre-clinical stage of development in addition to developmental candidate SUVN-502 for Alzheimer's disease and Schizophrenia.

For more information on Suven please visit our Web site at <http://www.suven.com>

#### *Risk Statement:*

*Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive;*